Recent Discoveries and Developments of Androgen Receptor-Based Therapy for Prostate Cancer

    January 2015 in “ MedChemComm ”
    R. Elancheran, V L Maruthanila, Meena Ramanathan, S. Kabilan, Rajlakshmi Devi, Ajaikumar B. Kunnumakara, Jibon Kotoky
    Image of study
    TLDR New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
    The document from 2015 reviews recent advancements in androgen receptor (AR)-based therapies for prostate cancer, including the development of new-generation AR antagonists like Enzalutamide (MDV3100) for advanced/metastatic prostate cancer, which is less toxic than chemotherapy. It discusses the emergence of castration-resistant prostate cancer (CRPC) and the need for novel AR antagonists to combat it. The review also covers the use of nonsteroidal antiandrogens, Luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, and the challenges of resistance to androgen deprivation therapy (ADT) through AR splice variants like AR-V7. Additionally, it mentions the potential of selective androgen receptor modulators (SARMs) and natural antiandrogens from plants as future treatments. Despite significant developments, the document concludes that further research is needed to improve the efficacy and reduce side effects of AR-based therapies for prostate cancer.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results

    Related Community Posts Join

    6 / 1000+ results

      community Anyone else crying themselves to sleep because of the pyrilutamide fail?

      in Technology  43 upvotes 11 months ago
      The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Does CosmeRNA target the root cause of MPB?

      in Chat 1 year ago
      . CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.

      community Pyrilutamide update: three months

      in Update  33 upvotes 1 year ago
      A user's 3-month experience with pyrilutamide to reduce hair shedding, and how it may not be strong enough to stop the thinning of their hairline. Other users mentioned the effectiveness of minoxidil and finasteride for treating hair loss.

    Similar Research

    5 / 1000+ results